Skip to main content

Table 1 Clinical characteristics of patients

From: Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer

 

Total

sTIL+

sTIL−

p

 

Gender

   

0.343

 

Male

145

69

76

  

Female

14

8

6

  

Median age (year, rang)

59.5 (24–84)

58.8 (38–84)

60.0 (24–77)

0.624

 

Clinical T stage

   

0.250

 

T1

16

10

6

  

T2

39

16

23

  

T3

52

21

31

  

T4

52

30

22

  

Mean Dmax-T (cm)

5.613

5.56

5.66

0.672

 

Clinical N stage

   

0.520

 

0

13

6

7

  

1

6

4

2

  

2

74

33

41

  

3

66

34

32

  

Clinical M stage

   

0.270

M0 versus M1

M0

90

46

44

  

M1

69

31

38

  

EM only

51

24

27

0.587

EM versus BM

BM only

8

4

4

  

EM and BM

10

3

7

  

Clinical TNM stage

   

0.301

 

I

1

1

0

  

II

4

1

3

  

III

86

44

42

  

IV

68

31

37

  

Regimen of CT

   

0.539

 

EP

107

50

57

  

EC

34

15

19

  

EN

6

4

2

  

IP

6

4

2

  

Others

6

4

2

  

Median cycles of CT (range)

4.7 (1–8)

4.7 (1–8)

4.7 (1–7)

0.870

 

TRT

   

0.173

 

No

77

33

44

  

Yes

82

44

38

  

Median dose of TRT (cGy, range)

5599 (3600–6900)

5595 (40,006–900)

5604 (3600–6400)

0.682

 

PCI

   

0.414

 

No

151

72

79

  

Yes

8

5

3

  
  1. BM, brain metastasis; CT, chemotherapy; Dmax-T, greatest dimension of tumor; EP, etoposide with cisplatin; EC, etoposide with carboplatin; EM, extracranial metastasis; EN, etoposide with nidaplatin; IP, irinotecan with cisplatin; TRT, thoracic radiotherapy